With a CDK4/6 inhibitor, abemaciclib, phase II trials are underway evaluating the effects of abemaciclib monotherapy or abemaciclib plus nivolumab in HPV(–) HNSCC (NCT03655444, NCT04169074). Here, CDK4 is linked to head and neck squamous cell carcinoma.